New COPD pill aims to cut Flare-Ups in half
NCT ID NCT07351734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a daily pill called JKN2403 can reduce serious flare-ups and improve quality of life in people with moderate-to-severe COPD. About 120 adults will take either the drug or a placebo for 24 weeks, with regular clinic visits and symptom diaries. The goal is to see if JKN2403 is safe and effective for managing this chronic lung disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JKN2403 tablets
- What this could lead to
- If successful, JKN2403 could become a new daily pill to reduce COPD flare-ups and improve breathing and quality of life.
- What could go wrong
- This is an early Phase IIa trial with only 120 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could remote rehab keep COPD patients out of the hospital?
- Chest vibrations may boost lung sample collection
- Sports-Inspired balance training could help COPD patients avoid falls
- Can remote care tame COPD Flare-Ups?
- Can a biologic clear the clogged airways of COPD?
- Can animated videos boost Self-Care in lung disease better than paper brochures?